| Literature DB >> 26203651 |
Farah Al-Marzooq1, Mohd Yasim Mohd Yusof1, Sun Tee Tay1.
Abstract
Infections caused by multidrug resistant Klebsiella pneumoniae have been increasingly reported in many parts of the world. A total of 93 Malaysian multidrug resistant K. pneumoniae isolated from patients attending to University of Malaya Medical Center, Kuala Lumpur, Malaysia from 2010-2012 were investigated for antibiotic resistance determinants including extended-spectrum beta-lactamases (ESBLs), aminoglycoside and trimethoprim/sulfamethoxazole resistance genes and plasmid replicons. CTX-M-15 (91.3%) was the predominant ESBL gene detected in this study. aacC2 gene (67.7%) was the most common gene detected in aminoglycoside-resistant isolates. Trimethoprim/sulfamethoxazole resistance (90.3%) was attributed to the presence of sul1 (53.8%) and dfrA (59.1%) genes in the isolates. Multiple plasmid replicons (1-4) were detected in 95.7% of the isolates. FIIK was the dominant replicon detected together with 13 other types of plasmid replicons. Conjugative plasmids (1-3 plasmids of ~3-100 kb) were obtained from 27 of 43 K. pneumoniae isolates. An ESBL gene (either CTX-M-15, CTX-M-3 or SHV-12) was detected from each transconjugant. Co-detection with at least one of other antibiotic resistance determinants [sul1, dfrA, aacC2, aac(6')-Ib, aac(6')-Ib-cr and qnrB] was noted in most conjugative plasmids. The transconjugants were resistant to multiple antibiotics including β-lactams, gentamicin and cotrimoxazole, but not ciprofloxacin. This is the first study describing the characterization of plasmids circulating in Malaysian multidrug resistant K. pneumoniae isolates. The results of this study suggest the diffusion of highly diverse plasmids with multiple antibiotic resistance determinants among the Malaysian isolates. Effective infection control measures and antibiotic stewardship programs should be adopted to limit the spread of the multidrug resistant bacteria in healthcare settings.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26203651 PMCID: PMC4512681 DOI: 10.1371/journal.pone.0133654
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
MICs ranges, MIC50 and MIC90 for the 93 multidrug resistant K. pneumoniae isolates investigated in this study.
|
|
| ||
|---|---|---|---|
| range | MIC50 | MIC90 | |
| Ceftazidime | 2–≥256 | 24 | ≥256 |
| Cefotaxime | 4–≥256 | ≥256 | ≥256 |
| Aztreonam | 4–≥256 | 48 | ≥256 |
| Piperacillin-tazobactam | 2–≥128 | 16 | ≥128 |
| Gentamicin | 0.19–≥256 | 24 | 96 |
| Amikacin | 0.5–≥256 | 4 | 16 |
| Ciprofloxacin | 0.032–≥32 | 2 | ≥32 |
| Trimethoprim/sulfamethoxazole | 0.125–≥32 | ≥32 | ≥32 |
Plasmid replicons and antibiotic resistance genes detected in 93 K. pneumoniae isolates.
|
| Antibiotic resistance genes (detection rates) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beta-lactamases | PMQR | Aminoglycosides | Cotrimoxazole | |||||||||||||||||
| Plasmid replicons | No. (%) of isolates | CTX-M-15 (91.3%) | CTX-M-3 (1.1%) | CTX-M-63 (1.1%) | SHV-12 (6.5%) | Other SHV types (72%) | TEM (63.4%) | OXA-1 (34.4%) | OXA-232 + NDM-1 (1.1%) | DHA-1 (2.2%) |
|
|
|
|
|
|
|
|
| |
| 0 | Non-typable | 4 (4.3) |
| ‒ | ‒ | ‒ |
|
|
| ‒ |
|
| ‒ |
|
| ‒ | ‒ | ‒ | ‒ |
|
| 1 |
| 50 (53.8) |
| ‒ | ‒ | ‒ |
|
|
| ‒ |
|
| ‒ |
|
| ‒ | ‒ |
|
|
|
| FIB-M | 2 (2.2) |
| ‒ | ‒ | ‒ |
|
|
| ‒ | ‒ |
| ‒ |
|
| ‒ | ‒ | ‒ |
|
| |
| N | 1 (1.1) |
|
| ‒ | ‒ |
| ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ |
|
| |
| 2 |
| 14 (15.1) |
| ‒ | ‒ | ‒ |
|
|
| ‒ | ‒ |
| ‒ |
|
| ‒ | ‒ |
|
|
|
|
| 3 (3.2) |
| ‒ | ‒ | ‒ |
|
|
| ‒ | ‒ |
| ‒ |
|
| ‒ | ‒ | ‒ |
|
| |
|
| 1 (1.1) |
| ‒ | ‒ | ‒ |
|
|
| ‒ | ‒ |
| ‒ |
|
| ‒ | ‒ | ‒ |
|
| |
|
| 1 (1.1) |
| ‒ | ‒ | ‒ |
|
| ‒ | ‒ | ‒ |
| ‒ |
|
| ‒ | ‒ | ‒ |
| ‒ | |
|
| 1 (1.1) |
| ‒ | ‒ | ‒ |
|
| ‒ | ‒ | ‒ | ‒ | ‒ |
|
| ‒ | ‒ | ‒ |
| ‒ | |
|
| 1 (1.1) |
| ‒ | ‒ | ‒ |
|
| ‒ | ‒ | ‒ | ‒ | ‒ | ‒ |
| ‒ | ‒ | ‒ | ‒ |
| |
|
| 1 (1.1) |
| ‒ | ‒ | ‒ |
|
| ‒ | ‒ | ‒ | ‒ | ‒ | ‒ |
| ‒ | ‒ |
| ‒ |
| |
|
| 1 (1.1) |
| ‒ | ‒ | ‒ |
|
| ‒ | ‒ | ‒ |
| ‒ | ‒ | ‒ | ‒ | ‒ | ‒ |
|
| |
|
| 1 (1.1) | ‒ | ‒ | ‒ |
| ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ |
|
|
| |
| HI2, Y | 1 (1.1) | ‒ | ‒ | ‒ |
| ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ |
|
|
| |
| 3 |
| 2 (2.2) | ‒ | ‒ | ‒ |
| ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ |
|
|
|
|
| 1 (1.1) |
| ‒ | ‒ | ‒ |
|
| ‒ | ‒ | ‒ | ‒ | ‒ | ‒ |
| ‒ | ‒ | ‒ |
|
| |
|
| 1 (1.1) |
| ‒ | ‒ | ‒ |
|
| ‒ | ‒ | ‒ | ‒ | ‒ | ‒ |
| ‒ | ‒ | ‒ |
|
| |
|
| 1 (1.1) |
| ‒ |
| ‒ |
| ‒ | ‒ | ‒ | ‒ | ‒ |
| ‒ | ‒ |
| ‒ | ‒ |
|
| |
|
| 1 (1.1) |
|
|
| ‒ |
|
| ‒ | ‒ | ‒ |
|
|
| ‒ | ‒ | ‒ | ‒ |
|
| |
|
| 1 (1.1) | ‒ | ‒ | ‒ |
| ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ |
|
| ‒ | ‒ | ‒ |
|
| |
|
| 1 (1.1) |
| ‒ | ‒ | ‒ |
|
|
| ‒ | ‒ |
| ‒ |
|
| ‒ | ‒ | ‒ |
|
| |
| FII, FIA, FIB | 1 (1.1) |
| ‒ | ‒ | ‒ |
|
|
| ‒ | ‒ |
| ‒ |
|
| ‒ | ‒ | ‒ |
|
| |
| 4 |
| 1 (1.1) | ‒ | ‒ | ‒ |
| ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ | ‒ |
|
|
|
| 1 (1.1) |
| ‒ | ‒ | ‒ |
| ‒ |
|
| ‒ |
| ‒ |
|
|
|
| ‒ |
|
| |
+: detected, ‒: not detected, V: variable (detected in some isolates but not detected in others), FIIK is in bold, *strain NDM-2012 [14], # strain K24 [13]. Other SHV types (non-ESBLs) included: SHV-1 (8.7%), SHV-11 (39.8%), SHV-27 (3.3%), SHV-28 (11.8%), SHV-75 (1.1%), SHV-83 (5.4%) and SHV-144 (1.1%).
The detection rates of IncF plasmid replicon alleles (FIIK, FII, FIA and FIB) in 93 K. pneumoniae isolates.
|
|
|
|
|---|---|---|
| FIIK-2 | None (44; 47.3) | K2: A-: B- |
| FII-10 (1; 1.1) | K2, F10: A-: B- | |
| FIIK-4 | None (1; 1.1) | K4: A-: B- |
| FIIK-5 | None (5; 5.4) | K5: A-: B- |
| FIIK-7 | None (21; 22.6) | K7: A-: B- |
| FIA-1 (1; 1.1) | K7: A1: B- | |
| FII-2, FIB-1 (1; 1.1) | K7, F2: A-: B1 | |
| FIIK-8 | None (5; 5.4) | K8: A-: B- |
| FIIK-9 | None (4; 4.3) | K9: A-: B- |
| FIIK-10 | None (1; 1.1) | K10: A-: B- |
| Negative | FII-1, FIA-1, FIB-16 (1; 1.1) | F1: A1: B16 |
| None (8; 8.6) | None |
n = number of isolates carrying each replicon,* Co-detected IncF replicons include FII, FIA and FIB. FAB (FII and/or FIIK: FIA: FIB) formula represents the allele type and number for each IncF replicon detected per isolate [10].
Characteristics of 43 donor K. pneumoniae isolates selected for conjugation experiments and the results of conjugation.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
|
| ‒ | ‒ | CTX-M-15 | 4 | N (2), |
|
| FIIK-8 | ‒ | CTX-M-15 | 5 | N (5) |
|
| ‒ | CTX-M-15 | 4 |
| |
|
| ‒ | CTX-M-15 | 2 |
| |
|
| ‒ | CTX-M-15 | 2 |
| |
| ‒ | FIB-M | CTX-M-15 | 2 | N (2) | |
|
| N | CTX-M-3 | 1 |
| |
|
|
| R | CTX-M-15 | 3 |
|
|
| FIB-M | CTX-M-15 | 1 |
| |
|
| HIB-M | CTX-M-15 | 1 |
| |
|
| R | CTX-M-15 | 1 |
| |
|
| N | CTX-M-15 | 1 |
| |
|
| FIB-M | CTX-M-15 | 1 |
| |
|
| I1 | CTX-M-15 | 1 |
| |
|
|
| CTX-M-15 | 1 |
| |
| FIIK-5 | HI2 | SHV-12 | 1 | N (1) | |
| ‒ | HI2, Y | SHV-12 | 1 | N (1) | |
|
| FIIK-4 | R, N | CTX-M-63 | 1 | N (1) |
|
| R, I1 | CTX-M-15 | 1 |
| |
|
| FIB-M, HIB-M | CTX-M-15 | 1 |
| |
|
| FII-2, FIB-1 | CTX-M-15 | 1 |
| |
| ‒ | FII-1, FIA-1, FIB-16 | CTX-M-15 | 1 | N (1) | |
|
| R, HI2 | CTX-M-15 | 1 |
| |
| FIIK-5 | HI2,Y | SHV-12 | 2 | N (2) | |
| FIIK-10 |
| SHV-12 | 1 |
| |
|
| FIIK-5 | R, FIB-M, HIB-M | CTX-M-15 | 1 | N (1) |
| FIIK-5 |
| SHV-12 | 1 |
| |
|
| 43 |
|
# non-typable plasmid in a transconjugant (no replicon was detected).
Y: successful conjugation, N: failed conjugation, ‒: no replicon was detected, n: number of isolates
Bold underlined text: replicons transferred to the transconjugants,
*: NDM-2012 strain
Comparison between K. pneumoniae donor isolates and their transconjugants (n = 27) with respect to non-susceptibility rates (%) and MICs of various antibiotics.
| Antibiotics | Non-susceptibility rates (%) | MICs (μg/ml) | |||
|---|---|---|---|---|---|
| D | T | D [range, MIC50, MIC90] | T [range, MIC50, MIC90] |
| |
| Ceftazidime | 96.3 | 96.3 | 4-≥256, 24, ≥256 | 1.5-≥256, 16, 32 | 0.5 |
| Cefotaxime | 100 | 100 | 16-≥256, ≥256, ≥256 | 8-≥256, 96, ≥256 | 0.125 |
| Aztreonam | 100 | 100 | 16-≥256, 48, ≥256 | 8-≥256, 48, 64 | 0.094 |
| Piperacillin-tazobactam | 29.6 | 0 | 3-≥128, 8, ≥128 | 2–4, 2, 4 | 2 |
| Ampicillin | 100 | 100 | ND | ND | S |
| Ceftriaxone | 100 | 100 | ND | ND | S |
| Cefuroxime | 100 | 100 | ND | ND | S |
| Cefoperazone | 100 | 100 | ND | ND | S |
| Amoxicillin-clavulanic acid | 96.3 | 96.3 | ND | ND | S |
| Ampicillin-sulbactam | 100 | 100 | ND | ND | S |
| Cefoxitin | 7.4 | 0 | ND | ND | S |
| Ciprofloxacin | 70.4 | 0 | 0.125-≥32, 2, ≥32 | 0.016–0.75, 0.19, 0.75 | 0.016 |
| Trimethoprim/sulfamethoxazole | 96.3 | 88.9 | 0.38-≥32, ≥32, ≥32 | 0.125-≥32, ≥32, ≥32 | 0.125 |
| Gentamicin | 48.1 | 40.7 | 0.25–96, 0.75, 64 | 0.25–64, 0.5, 48 | 0.25 |
| Amikacin | 0 | 0 | 1–16, 3, 8 | 1–8, 1.5, 3 | 1 |
ND: MIC testing was not done, D: K. pneumoniae (Donors), T: Transconjugants (E. coli strain J53 AzR), S: susceptible
Resistance determinants detected in the donors and transconjugants in this study.
| Antimicrobial category | Antibiotic resistance genes | Detection of resistance genes (n) in the donors ( | Detection of resistance genes (n) in the transconjugants ( |
|---|---|---|---|
| Beta-lactams | CTX-M-15 | 24 | 24 |
| CTX-M-3 | 1 | 1 | |
| TEM | 23 | 23 | |
| OXA-1 | 11 | 11 | |
| SHV-12 | 2 | 2 | |
| SHV-11 | 11 |
| |
| Aminoglycosides |
| 13 |
|
|
| 1 | 1 | |
| Fluoroquinolones |
| 18 |
|
|
| 15 | 15 | |
| Trimethoprim/sulfamethoxazole |
| 15 |
|
|
| 18 |
|
* ESBL genes, n: number of isolates. Bold underlined text: genes transferred from donors to some rather than all transconjugants, e.g. SHV-11 in 7 out of 11 donors was not transferred to their transconjugants.
Fig 1Dendrogram of EcoRI-digested plasmids from 27 transconjugants.
15 restriction profiles were identified (P1-P15). The dashed line represents the 80% similarity level used in cluster designation. Transconjugant plasmid ID, replicon and restriction profiles are shown.